Very strong rumours of a further predator around. CAT,WYEYH,JOHNSON&JOHNSON,MERCK to name a few.............could be an exciting week ...!

Its a Biotech in the research and dev stage so it will be loss making, the investment potential is all in the future possibilities with profits of 100s of millions if only one of their products reaches market. One of the best Biotechs you can invest in though with enormous potential and the institutions are coming round to realising that!

Keep an eye on Oxford Biomedica-oxb. On the rise (UPS) and potential break-out back to 46p.Late ground breaking announcement late today and more news expected.Buses arriving in threes comes to mind.

http://www.biotech-intelligence.com/html/html/9904d1fab80d627f5da59efaf1a2d3d4.html

http://www.advfn.com/p.php?pid=nmona&cb=1137613512&article=13842043&symbol=L%5EOXB

http://www.advfn.com/p.php?pid=nmona&cb=1137613512&article=13842549&symbol=L%5EOXB

Link to most recent charts by Fingers xxxd
http://www.advfn.com/cmn/fbb/thread.php3?id=5456944&from=3940

Wed 18 OXB 32.75p lex1000 Dropped from previous highs of 46p,placing @ 25p completed, institutional placing oversubscribed 2.5 times.Chart in rising trend.On the rise above major resistance at 32.5p and ground breaking news announced within last half hour of close.Back to 46p.

That would be nice :)

from Reuters:

http://investing.reuters.co.uk/investing/financeArticle.aspx?type=allBreakingNews&storyID=2006-01-18T162931Z_01_L18626054_RTRIDST_0_HEALTH-OXFORDBIO-VIRAGEN.XML


Biotech chicken advance boosts Oxford Bio, Viragen
Wed Jan 18, 2006 4:29 PM GMT
Printer Friendly | Email Article | RSS


LONDON, Jan 18 (Reuters) - Shares in Britain's Oxford BioMedica Plc (OXB.L: Quote, Profile, Research) and U.S.-based Viragen Inc (VRA.A: Quote, Profile, Research) gained on Wednesday following progress in a project to produce drugs in genetically modified hens' eggs.

BioMedica said a collaboration with Viragen and the Roslin Institute had, for the first time, produced significant quantities of interferon beta-1a in the whites of eggs laid by genetically modified chickens.

Interferon beta-1a is a key component of the human immune system and the active ingredient in several multiple sclerosis drugs.

Several biotech groups are working on ways to produce various complex protein drugs in milk, eggs or farm crops, as a cheap alternative to making them from cell cultures in stainless steel vats.

BioMedica shares gained 4.7 percent to 33-1/2 pence, while Viragen jumped 31 percent to 71 cents.

.

strong open.


Pharma sector to do well in 2006... FT
- OXB big Lentivector breakthrough- yesterday

- FT '2006 may well be a year for Growth stocks.. rally of several months in growth stocks likely'. Bios are 'Growth/defensive'.
.

tick up.2v2

OXB has not broken out...............yet.UBS declared no notifiable interest a few days ago and back above 3% today. Chart and rising trend intact.Support holding @{ 30p and waiting for hold and break above 33p. News can come at any time.

badday - 26 Jan'06 - 21:18 - 29262 of 29263


Scottie, not exactly the queens english, but i suspect that qpr will be very right!
There's an enormous amount of news building up, which could come at any time.

Dept of Health Funding
SPA approval from FDA for Trovax phase111 trials
Trovax deal
Approval for Prosavin trials
Metxia results
Additional funding for Monudin
And of course the usual surprises from Retinostat and Lentivectors.
With Results and AGM etc thrown into the pot the coming months should certainly not be lacking in interest.


8 Mar 2006 Center for Business Intelligence Gene Therapy Research Symposium
Cambridge, Massachusetts, USA

8-10 Mar 2006 BioSquare 2006
Geneva, Switzerland

28-30 Mar 2006 British Society for Gene Therapy (BSGT) Meeting
London, UK

29-30 Mar 2006 Ocular Anti-angiogenesis Meeting
London, UK

1-8 Apr 2006 58th Annual American Academy of Neurology Meeting
San Diego, California, USA

9-12 Apr 2006 BIO 2006 Annual International Convention
Chicago, Illinois, USA

30 Apr-4 May 2006 Association for Research in Vision and Ophthalmology (ARVO) 2006 Annual Meeting
Fort Lauderdale, Florida, USA



qpr67 - 26 Jan'06 - 21:25 - 29263 of 29263


badday

One more to note :

5-7 Feb 2006 4th Annual BioPartnering North America (BPN) Conference
Vancouver, Canada

badday - 27 Jan'06 - 07:30 - 29270 of 29278


Another bio bull

The highly regarded Findlay Park US Smaller Companies fund has bought almost 10% of International Biotechnology Trust in anticipation of an upturn in the biotech sector.

James Findlay, who is widely regarded as one the best US smallcap pickers operating out of London, told Citywire: 'We have a feeling that the biotechnology sector after several years will start to do a bit better.' He added, 'Our weakness is that we don't know much about individual technology or biotechnology companies.'

oxb back tested 30p,support held firm.On the rise again.

oxb continues 30p-32p.Post of excellent quality below.

elfman - 3 Feb'06 - 18:23 - 29766 of 29774


Davll2 sounds to that Ceregene is considerably behind in trials. Alzheimer treatment hasn't even entered phase1 !! Do you know the percentage of trials that make it from phase 1. This percentage increases with each stage with the likelihood of success related to the success of earlier phases. In the case of Trovax the phase 2 reults were so good that they will translate to a trial in renal and no phase 2b required. OXB PD (Parkinson's) model was 100% successful in standard animal trials (again indication of likely success therefore good) this will enter human trials later this year. When will Ceregene?
Innurex and Monudin have also recieved significant charitable trust support.
Retinostat has also had many plaudits.

By your own quote "The company was launched in January 2001 as a majority-owned subsidiary of Cell Genesys following the acquisition of Neurologic Gene Therapeutics, a private start-up company based in San Diego." So they are roughly 5 years behind OXB floatation which was not a start up at that time.

The DoH is so impressed with Trovax results they are about to cough up 66 million, what will that do to a company currently worth 120million (minus cash).
The Americans are so impressed that they have asked OXB to go for orphan status.

Some questions for you to research:

Which companies including bio's has Mike MacDonald worked for in the past and what were their market caps?

Who is running the phase 3 trial in renal cancer and how many papers has he published in the past on this subject (reflection of standing in this area and likelihood of getting involved with a non-starter. As you say plenty of trials to get involved with)?

How much is this market (renal) worth and how much of this market could OXB achieve (hint: see quote above)?

If the medical world did not believe the effect of Trovax would translate to other solid tumours why would they allow phase 2 colorectal to allow phase 3 renal?

If Trovax has an effect on other solid tumours, with minimal side effects what would this market be worth?

When is survival data due for Trovax?

What other approaches to cancer treatment does OXB have and how does it work?

What pharmaceutical awards was OXB nominated for best product pipeline and who were the other finalists?

How many other Lentivector systems do Sigmacon sell/promote and what is their standing in this area. Why did they take a stake in the company?

How much will the Viragen deal be worth (answer no-one knows but still worth taking into consideration).

It would seem to me that you have done more research in American bio's and my advice would be to put your money there.

OT
Where did you learn your Maths or can you see into the future? "OXB" were floated in 1996 and 11 or 12 years later are worth.. "


Whilst we are on maths, in the past the company has been at a 60% reduction to it's cash balance and IMHO it is equally undervalued in terms of worth at the present.

worth a specultive punt i reckon.

Link to details of 11 events through to June inclusive.
http://www.oxfordbiomedica.co.uk/events.htm

Chart looking oversold and months worth sp consolidating.Nice volumes and rise today.Easily sliced through resistance @ 32.5p and 35p next target.Watch for confimed breakout.

A year ahead and OXB's "Trovax" has a super-deal with the French pharma (Sanofi) and this is before the outcome of the PhIII trials in America. That's is a fantastic deal and the sp immediately went to 50p - although some might think it should have been higher...with the cash up-front of about 17m. Also huge potential Royalties, as the drug proves itself.. . .
However, Susan Kingsman has sold 4m shares just a bit under 48p and this has unsettled investors - of course there's "never" a good time for Directors to take a profit (by selling).....but this is odd:- it's a lot of shares and no explanation was forthcomming - well that's OK then...but the Market has pushed the sp lower on worries that she may know something about the outcome of the US_Trials expected later this year (or sooner, if bad!!! - Yikes!).
One has to say that that is unlikely and put to one side, but it seems odd (to me) not to wait until the PhIII trials are over - but that could mean delaying XXX (which isn't a yacht, I hear) - until the mid-winter.
It's a worry I think....but nothing that other companies don't do quite frequently...
I'm still holding, but keeping an eye on what's happening...so far I'v not reacted and not taken my profit, as I think the likelyhood is in favour of more up-side - My problem with selling is timing - I got it wrong with BTG[BGC] and ended up with a small loss! ( Had I waited longer I could have shown a profit but I didn't want to be "out" when the big deal arrives)....and that is far from time-certain.
That's it. . . . .
EDIT-(13Jy09)- almost Two years on, and OXB has found another product - this was "already there" - it's just that the Fr Authorities have got round to investigating ProSavin......All well and good, then.
For the Record, recently Trovax was handed-back, but oddly OXB was paid by Sanofi and they have taken on another product...ooer!